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Supplementary Results
Supplementary Figures
Supplementary Figure 1 . LC-MS profile of the IEDDA reaction between SCH-TCO and biotin-PEG4-tetrazine.
SCH-TCO (10 mM in MeOH, black) and biotin-PEG4-tetrazine (10 mM in MeOH, pink) were mixed in a 1:1 ratio for 5 min at r.t. The LC-MS profile of the crude mixture is shown in blue (a mixture of diastereoisomers is obtained).
Supplementary Figure 2. LC-MS profile of the IEDDA reaction between TCO-GDC-2 and biotin-PEG4-tetrazine.
TCO-GDC-2 (10 mM in MeOH, black) and biotin-PEG4-tetrazine (10 mM in MeOH, pink) were mixed in a 1:1 ratio for 5 min at r.t. The LC-MS profile of the crude mixture is shown in blue (a mixture of diastereoisomers is obtained).
Supplementary Figure 5. Target occupancy of ERK1/2 inhibitors in lysates.
HCT116 (B) and A375 (C) lysates were incubated with the indicated inhibitor for 1 h at 4 °C followed by incubation with SCH-TCO (1 µM) for 30 min at 4 °C. The levels of ERK1/2 pulled down during the protein enrichment experiments were quantified by densitometry from the immunoblottings (A) and plotted (B and C).
Supplementary Figure 6. Target occupancy of LY3214996 and GDC-0994 using TCO-GDC-2.
HCT116 lysates were incubated with the indicated inhibitor for 1 h at 4 °C followed by incubation with TCO-GDC-2 (1 µM) for 30 min at 4 °C. The levels of ERK1/2 pulled down during the protein enrichment experiments were quantified by densitometry from the immunoblottings.
Supplementary Figure 7. Ability of SCH-TCO to pull down ERK1/2 after in-cell treatment.
A. HCT116 cells were incubated with SCH-TCO (1 h). Following cell lysis and coupling with tetrazine beads (30 min at 4 °C), proteins bound to SCH-TCO were pulled down and separated on 4-12% NuPAGE gels. Immunoblots for ERK1/2 are shown. Proteins unspecific binding to the beads (background noise) is shown as 'cell lysates through filter' on the figure. B. HCT116 cells were incubated with SCH-TCO for 15, 30, 45 or 60 min. Following cell lysis and coupling with tetrazine beads (30 min at 4 °C), proteins bound to SCH-TCO were pulled down and separated on 4-12% NuPAGE gels. Immunoblots for ERK1/2 are shown.
Supplementary Figure 8. Effect of incubation time on target engagement.
HCT116 cells were treated with GDC-0094 for 1h or 1h30 followed by SCH-TCO (1 µM, 15 min). After cell lysis and pull down, the levels of ERK1/2 were quantified by densitometry from the immunoblotting.
Supplementary Figure 9. Effect of cell lysis on ERK1/2 pull down using SCH-TCO in cells.
When lysates are treated with the untagged inhibitor followed by SCH-TCO, the probe binds to the remaining free ERK1/2 (normal conditions). The same phenomenon happens after in-cell treatment. However, in this case, cell lysis must occur after drug/probe treatments. It is postulated that the cell lysis perturbs the binding of the inhibitor with the protein resulting in higher SCH-TCO protein interactions. The apparent target engagement of the inhibitor is therefore lower than in reality.
Supplementary Figure 10. Potential issue during ERK1/2 pull down with TCO-GDC-2.
With a covalent probe, the protein is tightly linked to the protein preventing dissociation of the whole complex during pull down (normal conditions). TCO-GDC-2 being a non-covalent probe, it is likely that the complex TCO-GDC-2/protein/beads dissociates during pull down. Less protein is pulled down resulting in higher apparent engagement.
Supplementary Figure 11. CETSA melting curves.
CETSA melting curves for ERK1 and 2 in HCT116 lysates (A) and cells (C) after treatment with either DMSO or the selected ERK1/2 inhibitors (10 µM, 15 min). Immunoblot showing the levels of ERK1 and ERK2 remaining soluble in HCT116 lysates (B) and cells (D) after heating in the presence of DMSO or ERK1/2 inhibitors.
Supplementary Figure 12. Target occupancies of ERK1/2 inhibitors in lysates by CETSA.
In lysates ERK1 and ERK2 occupancies of SCH772984, GDC-0994 and LY3214996 determined by ITDR-CETSA.
Experimental procedures
Synthesis of TCO tagged probes derived from SCH772984
TCO-SCH probe was synthesised via a convergent synthetic route as outlined in Supplementary Scheme 1. Pyrimidine 1 and boronic ester 2 reacted under Suzuki conditions followed by deprotection of the piperazine moiety using acid and amide formation with chloroacetyl chloride which led to chloro derivative 4. Boc protected proline 5 was converted in a one-pot procedure into the methyl ester proline hydrochloride salt 6 which was reacted with chloro intermediate 4. The product of the nucleophilic substitution was consequently hydrolysed under basic conditions to give acid 7 as a lithium salt. The nitro derivative 9 was synthesised from nitro indazole 8 which was first protected with a trityl group then reacted under Suzuki conditions with the appropriate boronic ester. Reduction of the nitro group under catalytic hydrogenation led to aniline 10 which was reacted with acid 7 under amide coupling conditions. Trityl deprotection using acid, basic hydrolysis of the ester group and final amide coupling to insert the TCO tag afforded TCO-SCH probe. 
Supplementary
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Synthesis of TCO tagged probes derived from GDC-0994
Both TCO tagged probes were synthesised from a common intermediate, the aminopyrimidine 27, obtained from a convergent route as shown in Supplementary Scheme 3. Suzuki coupling between 4-bromopyrimidine 17 and boronic acid 18 followed by hydration of the pyridine ring through displacement of the fluoro group by water in acidic environment led to the hydropyridine 19. The diol 22 was obtained from aldehyde 20 which underwent a Wittig reaction followed by a Sharpless asymmetric dihydroxylation using AD-mix β. Protection of the primary alcohol with a silyl group and mesylation of the secondary alcohol led to intermediate 24 which, after nucleophilic substitution by hydropyridine 19, gave pyrimidine 25. After oxidation of the methyl sulphur into the methyl sulfone with m-CPBA and nucleophilic displacement by using ammonium hydroxide, the aminopyrimidine 27 was synthesised.
Buchwald coupling between aminopyrimidine 27 and bromopyridine 28 followed by TBDMS deprotection using acid, basic hydrolysis of the ester group and finally amide coupling with TCO-amine led to the TCO tagged probe TCO-GDC-1.
Regioselective Sonogashira coupling between 2,4-dibromopyridine 29 and tert-butyl but-3-ynyl carbamate gave bromopyridine 30 which then underwent a Buchwald coupling with aminopyrimidine 27. Dual removal of TBDMS and Boc protecting groups in acidic conditions followed by reaction with TCO-NHS ester led to the second TCO tagged probe, TCO-GDC-2. 
General Notes for Syntheses
Anhydrous solvents were purchased either from VWR or SeccoSolv and were stored under nitrogen. Other solvents were purchased from Fisher Chemicals. Commercially available reagents were used as received. TCO-Amine and TCO-NHS ester were purchased from Jena Bioscience. Petrol refers to the fraction with a boiling range between 40 and 60 ºC. All reactions were followed by TLC analysis (pre-coated TLC sheets ALUGRAM ® SIL G/UV 254 , Macherey-Nagel) or LC-MS (liquid chromatography mass spectrometry) on Agilent 1200 HPLC and 6140 MS using a YMC-Triart C18 column (50 x 2.0 mm, 1.9 µm). 1 H NMR spectra were recorded on a Bruker 400 UltraShield TM spectrometer. Chemical shifts are reported in parts per million (δ) referenced to the appropriate deuterated solvent employed and relative to TMS. Multiplicities are indicated by s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet). 'Flash' column chromatography was performed on pre-packed silica cartridges (Biotage SNAP cartridges, KP-Sil) on Biotage Isolera Four. All reactions were carried out under nitrogen.
The purity of the final probes was determined by LC-MS and 1 H NMR and was always >95%.
LC-MS methodology
Eluent A: 10 mmoL ammonium bicarbonate pH 9. 50 mmol) was dissolved in DCM (4.2 mL) and HCl in dioxane (4M, 1.67 mL) was added. The reaction was stirred at room temperature for 2 hours and the solvent was removed in vacuo to give 2- [4-(piperazin-1-yl) Propionyl chloride (2.0 mL, 23.3 mmol) was added dropwise to an ice-cold solution of (R)-1-Nboc-beta-proline 5 (1.0 g, 4.7 mmol) in dry MeOH (18 mL). The reaction was allowed to warm up to room temperature and was stirred for 18 hours. The solvent was removed in vacuo to give methyl (3R)-pyrrolidine-3-carboxylate hydrochloride 6 (0.8 g, 4.6 mmol, 99%) as a pale orange oil. 2-Chloro-1-{4-[4-(pyrimidin-2-yl)phenyl]piperazin-1-yl}ethan-1-one 4 (0.54 g, 1.69 mmol) was solubilised in dry MeCN (7.6 mL). N,N-Diisopropylethylamine (0.73 mL, 4.22 mmol) and methyl (3R)-pyrrolidine-3-carboxylate hydrochloride 6 (0.42 g, 2.53 mmol) were added, followed by potassium iodide (0.56 g, 3.38 mmol). The reaction was stirred at room temperature for 2 hours. EtOAc (10 mL) and water (10 mL) were added and the organic phase was extracted with EtOAC (2 x 10 mL) then dried over MgSO 4 . The solvent was removed in vacuo and the crude product was purified by flash column chromatography with 1: 9 MeOH: EtOAc to give methyl ( Trityl chloride (15.8 g, 56.5 mmol) and potassium carbonate (10.4 g, 78.5 mmol) were added to a stirred solution of 3-bromo-5-nitro-1H-indazole 8 (3.8 g, 15.7 mmol) in MeCN (100 mL). The reaction was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the crude was partitioned between water (50 mL) and DCM (50 mL). The organic phase was extracted with DCM (2 x 50 mL), dried over MgSO 4 and the solvent was removed in vacuo. The resulting solid was washed with a solution of 20% EtOAc in Petrol and with a solution of 5% EtOAc in Petrol to give 3-bromo-5-nitro-1-(triphenylmethyl)-1H-indazole (7.5 g, 15.5 mmol, 98%) as a pale yellow solid. 
LCMS
Procedure for TCO-SCH: (4E)-cyclooct-4-en-1-yl N-{3-[(4-{5-[(3R)-1-(2-oxo-2-{4-[4-(pyrimidin-2-yl) phenyl]piperazin-1-yl}ethyl)pyrrolidine-3-amido]-1H-indazol-3-yl}pyridin-2-yl) formamido]propyl}carbamate.
pyridine-2-carboxylate 10 (0.22 g, 0.43 mmol), N,N-diisopropylethylamine (0.20 mL, 1.12 mmol), EDCI.HCl (0.12 g, 0.65 mmol) and HOAt (0.09 g, 0.65 mmol) were mixed in dry DMF (3.9 mL) and the reaction was stirred at room temperature for 24 hours. The solvent was removed in vacuo and the crude product was purified by semi-preparative HPLC using 45-80% MeCN to give methyl 4-{5- 09 mmol) were mixed in dry DMF (0.6 mL) and the reaction was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the crude product was purified by semi-preparative HPLC using 5-95% MeCN to give (4E)- 38, 167.62, 163.88, 163.14, 157.17, 155.57, 152.26, 150.35, 149.00, 142.31, 139.42, 138.66, 134.75, 133.74, 132.38, 128.68, 127.07, 122.40, 120.45, 120.25, 118.37, 118.07, 114.27, 108.48, 78.82, 57.11, 56.83, 53.15, 47.38, 47.01, 44.34, 43.61, 40.60, 40.56, 38.00, 37.66, 36.31, 33.50, 32.01, 30.46, 29.66, 27.56, 11.17 . Benzyl N-[2-(methanesulfonyloxy)ethyl]carbamate (2.1 g, 7.7 mmol) was added to a stirred suspension of potassium carbonate (1.6 g, 11.5 mmol) and 2-chloro-5-hydroxypyrimidine (0.5 g, 3.8 mmol) in dry DMF (7.7 mmol). The reaction was stirred at 70 ºC for 18 hours. Water (10 mL) and EtOAc (15 mL) were added and the organic phase was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with brine (3 x 30 mL) and dried over MgSO 4 . The solvent was removed in vacuo and the crude product was purified by flash column chromatography with 2: [(2-chloropyrimidin-5-yl) oxy]ethyl}carbamate 12 (1.1 g, 3.7 mmol) and potassium carbonate (2.3 g, 17.0 mmol) were added to a stirred solution of tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]tetrahydro-1(2H)-pyrazinecarboxylate (1.1 g, 2.8 mmol) in DMF/H2O (1: 1, 19 mL). N 2 was bubbled in the reaction for 5 min then [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.2 g, 0.3 mmol) was added. The reaction was heated at 80 ºC for 2.5 hours. After completion, the reaction was cooled to room temperature, diluted with water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (3x 30 mL), dried over MgSO 4 Chloroacetyl chloride (0.09 mL, 1.15 mmol) was added to a solution of benzyl N- [2-({2-[4-(piperazin-1-yl) phenyl]pyrimidin-5-yl}oxy)ethyl]carbamate hydrochloride (0.49 g, 1.05 mmol) and N,N-diisopropylethylamine (0.42 mL, 2.41 mmol) in dry MeCN (7.00 mL). The reaction was stirred at room temperature for 30 min. Water (10 mL) was added and the organic phase was extracted with EtOAc (2 x 10 mL). The organic phase was dried over MgSO 4 Benzyl
Synthesis of SCH-TCO
Procedure for Compound 13: tert-Butyl 4-{4-[5-(2-{[(benzyloxy)carbonyl]amino}ethoxy)pyrimidin-2-yl]phenyl}piperazine-1-carboxylate.
N N N N O O O N H O O Benzyl N-{2-
N-{2-[(2-{4-[4-(2-chloroacetyl)piperazin-1-yl]phenyl}pyrimidin-5-yl)oxy]ethyl}
carbamate 14 (0.28 g, 0.55 mmol) was solubilised in dry MeCN (2.5 mL). N,NDiisopropylethylamine, (0.29 mL, 1.66 mmol), methyl (3R)-pyrrolidine-3-carboxylate hydrochloride 6 (0.14 g, 0.83 mmol) followed by potassium iodide (0.18 g, 1.11 mmol) were added. The reaction was stirred at room temperature for 16 hours. EtOAc (10 mL) and water (10 mL) were added and the organic phase was extracted with EtOAC (3 x 10 mL). The organic phases were combined, dried over MgSO 4 and the solvent was removed in vacuo. 3-(Pyridin-4-yl)-1-(triphenylmethyl)-1H-indazol-5-amine (0.27 g, 0.45 mmol) was solubilised in MeOH (9 mL) and 1N LiOH (2.8 mL) was added. The reaction was stirred at r.t. for 3 days. 1M HCl was added (2.8 mL) and the solvent was removed in vacuo to give (3R)-1-[2- (4-{4-[5-(2-{[(benzyloxy) (4, 4, 5, 3 ,2-dioxaborolan-2-yl)-pyridine (0.8 g, 4.1 mmol) and sodium carbonate (2.2 g, 20.7 mmol) were added to a stirred solution of 3-bromo-5-nitro-1-(triphenylmethyl)-1H-indazole (2.0 g, 4.1 mmol) in DME (41 mL). N 2 was bubbled in the reaction for 5 min then [1,1′-bis(diphenylphosphino) ferrocene]dichloropalladium(II) in complex with CH 2 Cl 2 (1.3g, 1.7 mmol) was added. The reaction was heated at 90 ºC for 16 hours. After completion, the reaction was cooled to room temperature, diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (100 ML), dried over MgSO 4 and the solvent was removed in vacuo. The crude product was purified by flash column chromatography with 2: 3 EtOA: Petrol to give 5-nitro-3-(pyridin-4-yl)-1-(triphenylmethyl)-1H-indazole (1.1 g, 2.3 mmol, 55%) as a yellow solid.
LCMS: Retention time 1.67 min, [M+H] + = 483
To a mixture of 5-nitro-3-(pyridin-4-yl)-1-(triphenylmethyl)-1H-indazole (1.1 g, 2.3 mmol) and 10% Pd/C (0.3 g) in MeOH (14 mL) and EtOAc (4 mL) was added ammonium formate (1.1 mL, 22.6 mmol). The mixture was refluxed for 3 hours and the catalyst was removed by filtration on Celite. The filtrate was concentrated in vacuo. The crude product was purified by flash column chromatography with 100 EtOAc to give 3-(pyridin-4-yl Cyclooct-4-en-1-yl N-[2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl) 45 mmol) were mixed in dry DMF (2.7 mL) and the reaction was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the crude product was purified by semi-preparative HPLC using 55-90% MeCN to give benzyl N- [2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl Trifluoroacetic acid (0.15 mL) was added to a solution of benzyl N- [2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl 
Procedure for SCH-TCO: (4E)-
piperazin-1-yl)phenyl]pyrimidin-5-yl}oxy)ethyl]carbamate (0.14 g, 0.14 mmol) in DCM (1.1 mL). The reaction was stirred at room temperature for 1 hour. After completion, the solvent was removed in vacuo. The crude product was purified by flash column chromatography with 1:4 MeOH: DCM to give benzyl N- [2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl Benzyl N- [2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl)-1H-indazol-5-yl] carbamoyl}pyrrolidin-1-yl]acetyl}piperazin-1-yl)phenyl]pyrimidin-5-yl}oxy)ethyl] carbamate (0.11g, 0.14 mmol) and 10% Pd/C (0.05 g) were mixed in MeOH (0.7 mL) under an atmosphere of H 2 for 5 hours. The catalyst was removed by filtration on Celite and the filtrate was concentrated in vacuo to [3-(pyridin-4-yl)-1H-indazol-5-yl] pyrrolidine-3-carboxamide (0.08 g, 0.13 mmol, 92%) as a yellow oil.
LCMS: Retention time 1.26 min, [M+H] + = 647
Note: 6H missing -under solvent peaks TCO-NHS ester (9.0 mg, 0.03 mmol) was added to a stirred solution of (3R)
(21.0 mg, 0.03 mmol) and N,Ndiisopropylethylamine (14.0 µL, 0.08 mmol) in dry DMF (0.8 mL). The reaction was stirred at room temperature for 1 hour. The crude was purified by semi-preparative HPLC using 5-95% MeCN to give (4E)-cyclooct-4-en-1-yl N- [2-({2-[4-(4-{2-[(3R)-3-{[3-(pyridin-4-yl 
pyrimidin-5-yl}oxy)ethyl] carbamate (9.6 mg, 0.01 mmol, 37%) as a yellow oil. 08 mmol) in EtOAc (4.1 mL). The reaction was stirred at room temperature for 2 hours (until completion) and the solvent was removed in vacuo. The crude product was partitioned between EtOAc (10 mL) and a saturated solution of NaHCO 3 (10 mL). The organic phase was extracted, dried over MgSO 4 and the solvent was removed in vacuo. The crude product was purified by flash column chromatography using 1: 9 MeOH: DCM to give methyl 4-[(4-{1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-2-oxo-1,2-dihydropyridin-4-yl}pyrimidin-2-yl)amino] pyridine-2-carboxylate (0.03 g, 0.05 mmol, 64%) as a yellow oil. 13 C NMR (101 MHz, DMSO-d 6 ) δ ppm 163.78, 161.57, 161.28, 160.05, 159.43, 157.05, 155.58, 150.31, 148.50, 148.40, 146.42, 139.44, 136.82, 134.62, 132.25, 130.48, 124.79, 118.53, 117.43, 115.77, 113.91, 110.65, 110.41, 102.64, 78.73, 60.47 (x2), 58.64, 40.43, 38.02, 37.62, 36.17, 33.45 (x2), 30.36 (x2), 31.92, 29.43 . [4-(4-bromopyridin-2-yl)but-3-yn-1-yl] carbamate 30 (0.04 g, 0.12 mmol), potassium carbonate (0.03 g, 0.25 mmol), Xphos (3 mg, 0.01 mmol) and Pd(dba) 2 (4 mg, 0.01 mmol) were mixed in dry MeCN (1.3 mL). The reaction was purged with nitrogen for 5 min and heated at 80 ºC for 18 hours. The crude mixture was filtered and the solvent was removed in vacuo. The crude product was purified by flash column chromatography using 7:
Note -OH not determined
Synthesis of TCO-GDC
